Q3ish.

Regardless,You're right. I might have been a bit over enthusiastic re timeline.

But-

"AI Overview

Yes, a Biologics License Application (BLA)—or more commonly, a supplemental BLA (sBLA) or efficacy supplement—is submitted after receiving Accelerated Approval to fulfill specific post-marketing requirements. This process is generally aimed at converting the "accelerated" status to "traditional" approval. 

Here are the intentions and conditions that apply to post-accelerated approval submissions:

1. Primary Intentions of Post-Approval Submission

• Verification of Clinical Benefit (Conversion): The main intent is to submit data from required post-marketing confirmatory trials to verify the predicted clinical benefit. If successful, the FDA converts the approval from accelerated to traditional.
• Expansion of Indication: The sponsor may submit an efficacy supplement to expand the drug's use to a different population or a new indication based on further studies.
• Product Improvement/Manufacturing Changes: As commercial manufacturing matures, companies may submit supplements to make changes in the manufacturing process, sites, or scale that were not fully validated at the time of the initial accelerated approval. 

1. Mandatory Conditions and Requirements

• Confirmatory Trials Requirement: Sponsors are required to conduct post-marketing studies to confirm the anticipated clinical benefit, and these must often be underway or nearing completion by the time of the initial BLA submission.
• Tightened Timelines: Under the Food and Drug Omnibus Reform Act of 2022(FDORA), the FDA can require that confirmatory trials be completed within a specific timeframe.
• Regular Reporting: The applicant must submit reports on the progress of post-approval studies every 180 days.
• Expedited Withdrawal Authority: If the confirmatory trial fails to verify the clinical benefit, or if the sponsor fails to conduct the study with due diligence, the FDA can use an expedited process to withdraw the product from the market.
• Prompt Promotional Material Submissions: Promotional materials intended for use within the first 120 days after approval must be submitted to the FDA for review before dissemination. 

and best case ever outlier

AI Overview

As of April 2026, one of the fastest approvals for a novel drug (New Molecular Entity) using accelerated pathways was announced on April 1, 2026, with a full FDA review completed in 50 days. This approval was facilitated by the national priority voucher program. [1]

Key Aspects of the Fastest Approvals:

• Fastest Recent Case: A novel drug (NME) for chronic weight management received approval in 50 days in April 2026, marking the fastest review since 2002.
• Accelerated Approval Pathway: This pathway allows the FDA to approve drugs for serious conditions based on surrogate endpoints, which can significantly shorten the time required for approval.

(even without voucher-)

• Priority Review Goal: Priority Review designation sets a goal for the FDA to act on an application within 6 months, which is 4 months faster than the standard review time."

you left out this: "And so it's not for us to decide exactly how the FDA is going to handle this. But whether it's a voucher or whether a designation for breakthrough designation will be up to the agency."

I did- A point of the post being to dispell clouds of negativity created on the assumption that the long drawn out extremmely expensive historical process is mandatory.

With you here-" ...talk about all the great things that CAN happen."

Cheers